# A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Study · id `cardio:ct-nct07281937` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07281937](<https://clinicaltrials.gov/study/NCT07281937>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07281937

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

## Technical summary

Registry record NCT07281937. Randomized; triple masking; primary purpose treatment. Start 2025-11-25 (actual); primary completion 2026-07-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 206 participants (enrolled count; ClinicalTrials.gov record NCT07281937, source copy `cardio:ctgov-nct07281937-2026-08-17`, retrieved 2026-10-26)
- Started: 2025-11-25 (actual) (ClinicalTrials.gov record NCT07281937, source copy `cardio:ctgov-nct07281937-2026-08-17`, retrieved 2026-10-26)
- Primary completion: 2026-07-23 (actual) (ClinicalTrials.gov record NCT07281937, source copy `cardio:ctgov-nct07281937-2026-08-17`, retrieved 2026-10-26)
- Completion: 2026-07-23 (actual) (ClinicalTrials.gov record NCT07281937, source copy `cardio:ctgov-nct07281937-2026-08-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07281937, source copy `cardio:ctgov-nct07281937-2026-08-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07281937-2026-08-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- Acronym: EVOLVE-2
- Condition: Obesity
- Condition: Overweight
- Intervention (Drug): VRB-101
- Intervention (Drug): Placebo
- Lead sponsor: Verdiva Bio Dev Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: b5a241370f480654889d46c37caa54cda2d493cf94db6b361367fc286387f08a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
